miRNA-21 regulates CD69 and IL-10 expression in canine leishmaniasis

PLoS One. 2022 Mar 24;17(3):e0265192. doi: 10.1371/journal.pone.0265192. eCollection 2022.

Abstract

Visceral leishmaniasis in humans is a chronic and fatal disease if left untreated. Canine leishmaniasis (CanL) is a severe public health problem because infected animals are powerful transmitters of the parasite to humans via phlebotomine vectors. Therefore, dogs are an essential target for control measures. Progression of canine infection is accompanied by failure of cellular immunity with reduction of circulating lymphocytes and increased cytokines that suppress macrophage function. Studies showed that the regulation of the effector function of macrophages and T cells appears to depend on miRNAs; miRNA-21 (miR-21) shows increased expression in splenic leukocytes of dogs with CanL and targets genes related to the immune response. Mimics and inhibitors of miR-21 were used in vitro to transfect splenic leukocytes from dogs with CanL. After transfection, expression levels of the proteins FAS, FASL, CD69, CCR7, TNF-α, IL-17, IFN-γ, and IL-10 were measured. FAS, FASL, CD69, and CCR7 expression levels decreased in splenic leukocytes from dogs with CanL. The miR-21 mimic decreased CD69 expression in splenic leukocytes from CanL and healthy groups. The miR-21 inhibitor decreased IL-10 levels in culture supernatants from splenic leukocytes in the CanL group. These findings suggest that miR-21 alters the immune response in CanL; therefore, miR-21 could be used as a possible therapeutic target for CanL.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Dog Diseases* / parasitology
  • Dogs
  • Interleukin-10 / genetics
  • Interleukin-10 / therapeutic use
  • Leishmania infantum*
  • Leishmaniasis* / veterinary
  • Leishmaniasis, Visceral* / drug therapy
  • Leishmaniasis, Visceral* / genetics
  • Leishmaniasis, Visceral* / veterinary
  • MicroRNAs* / genetics
  • MicroRNAs* / therapeutic use
  • Receptors, CCR7

Substances

  • MicroRNAs
  • Receptors, CCR7
  • Interleukin-10

Grants and funding

This work was supported by São Paulo Research Foundation (FAPESP) (www.fapesp.br), grant 2018/17261-5 and 2018/16239-6; National Council for Scientific and Technological Development (CNPq), process 302165/2018-5 and 140460/2018-7. This study was also partially financed by the Coordination for the Improvement of Higher Education Personnel (CAPES) - Finance Code 001 (student supported: (GTR, JHF, MOS, SFC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. VMFL GRANT FAPESP 2018/17261-5 JPB SCHOLARSHIP FAPESP 2018/16239-6.